Astromech is valued at $3.8 billion after raising $20 million in a round announced August 20, 2026, up from $2 billion in March 2026, and the Colossal Biosciences spinout has raised $60 million in total with no disclosed revenue.
That ratio is the story: a $20 million check priced the company at 190 times the amount raised. Astromech was co-founded by Colossal CEO Ben Lamm and Harvard geneticist George Church to build AI that forecasts how living systems change over time. Investors are paying for the team, the Colossal data pipeline and the idea, because there are no customers yet.
Astromech Valuation: $3.8 Billion in August 2026
"An artificial intelligence startup called Astromech that's developing models that can predict biological change has raised $20 million in funding, lifting its valuation to $3.8 billion," SiliconANGLE reported on August 20, 2026. The round "was led by biotechnology investor Bob Nelsen and saw the participation of Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, bringing the company's total amount raised to date to $60 million." Astromech was valued at $2 billion in March 2026, per Tech Funding News on July 21, 2026.
Astromech Funding History
| Date | Event | Amount | Valuation | Investors / source |
|---|---|---|---|---|
| 2025 | Spun out of Colossal Biosciences | Not disclosed consistently | — | Co-founders Ben Lamm, George Church |
| Mar 2026 | Funding round | Not confirmed | $2B | Tech Funding News |
| Aug 20, 2026 | Funding round | $20M | $3.8B | Bob Nelsen (lead), Peak 6, NeoGenesis Capital, Builders VC, CAZ Investments (SiliconANGLE) |
| Total | All rounds | $60M | — | SiliconANGLE, Tech Funding News |
Sources disagree on Astromech's earlier round sizes: a September 2025 company press release announced $30 million, and an April 2026 headline reported $40.5 million at $2 billion, which together with the $20 million would exceed the $60 million total that SiliconANGLE and Tech Funding News report. We list only the figures the August 2026 coverage states.
What Does Astromech Do?
Astromech builds what its founders call a "predictive model of biology." Per SiliconANGLE, the model "crunches a combination of genomic, evolutionary, biological and functional data to try to anticipate how living systems will change over time." Lamm framed it this way: "Think of it like the weather, a complex system that humanity can predict due to specific technology and datasets. We are building the same thing for biology with evolutionary data."
Its first public demonstration mapped 46 longevity-associated genes across species that solved the same problem differently, including cancer-resistant Asian elephants, bowhead whales that live two centuries and Brandt's bats that live past forty, The Next Web reported on August 21, 2026. In retrospective validation, the pipeline "recovered trait-associated genes already established in published research and flagged further candidates."
Does Astromech Have Revenue?
Revenue: not disclosed. "No partner pilot has been named, and no customer has been announced in health, biosecurity, agriculture or conservation," The Next Web wrote on August 21, 2026. It added that "no forecast has been tested prospectively," and that a claimed 100-times speed figure is an internal benchmark Astromech has not published for outside review. At $3.8 billion with no product revenue, Astromech's price rests on the founders' record and on access to Colossal's genomic work.
How Does Astromech Compare to Colossal Biosciences?
Astromech's parent is far larger. Colossal Biosciences, which is working to de-extinct species such as the woolly mammoth and the dodo, carried a $10.2 billion valuation after its $200 million Series C in January 2025, and it was reportedly in talks to raise at a valuation of $20 billion to $30 billion in July 2026, according to Axios, as cited by Tech Funding News. See the full Colossal Biosciences company profile for its funding history.
Will Astromech IPO?
No IPO has been announced as of October 20, 2026, and Astromech has not filed with the SEC to go public. With $60 million raised and no commercial product, an IPO would be unusual in the near term; the next marker is a priced round from new institutional investors or a first named customer.
Where I Could Be Wrong
Small rounds at high prices can overstate value: a $20 million check sets the price for a sliver of the company, and terms such as liquidation preferences are not public. On the other side, Lamm has turned Colossal into a company reportedly worth tens of billions without a commercial de-extinction product, so markets have priced this team's story highly before. The test for Astromech is a prospective prediction that turns out right, or a paying customer.
Explore Related Dashboards
Interactive tools with live data on this topic
Track AI startup valuations on the AI Valuations Dashboard at Value Add VC. Our Pulse story on the round is here.
Latest from the Pulse
Get VC data most people never see
— free to subscribe
Trace's notes on venture, AI and startups, a few times a week. Join 5,000+ subscribers. No spam.
No spam, unsubscribe anytime. Sent via Substack · Privacy · or subscribe on Substack ↗